Danaher announced a strategic partnership with the University of Pennsylvania focusing on cell therapy innovation. The multi-year partnership aims to develop new technologies that will improve the consistency of clinical outcomes for patients and overcome manufacturing bottlenecks in the delivery of next generation engineered cell products.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DHR:
- Danaher Announces Quarterly Dividends
- Catalent price target raised to $78 from $60 at BofA
- Jefferies says Catalent could be valued near $93 on average CDMO buyout multiple
- CTLT Soars on Danaher Interest; Will Publish Q2 Numbers Tomorrow
- Premium required for any Catalent-Danaher deal ‘up for debate,’ says BofA